Skip to content
DataLookout
Menu

salVageNCT06114108

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Dec 21, 2023 to Feb 19, 2024 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 13 words
    • Interventions modified
    • Secondary endpoints: 5 to 17
    • Study description expanded, about 14 words
    • Study title expanded, about 2 words
  2. Notable Eligibility criteria expanded, about 24 words
    • Study completion date: Nov 1, 2027 to Mar 1, 2028
    v7
  3. Minor Study sites: 8 to 7v5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2024 to Dec 21, 2023
    • Site details revised at 8 of 8 sites
    v3
  5. Notable Start date: Nov 1, 2023 to Feb 1, 2024v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS): superiority of local ablative therapy (LAT) plus standard of care (SoC) versus SoC alone
Timeframe: up to 24 months after randomization
Quality of life (QoL): non-inferiority of LAT plus SoC versus SoC alone, measured with the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) index score
Timeframe: 6 months after randomization

Secondary (17)

EORTC QLQ-C30 Global Health Status/Quality of Life Score
EORTC QLQ-LC13 Symptom Scale Scores
EQ-5D-5L Index Score Over Time
EQ-5D Visual Analogue Scale (EQ VAS) Score
FACT-L Total Score
Show 12 moreShow less
Agreement Between Quality of Life Reported in the "My Cancer Companion" App and PROM Scores
Number of Participants With Grade ≥ 3 Surgical Complications (Clavien-Dindo)
Number of Participants With Grade ≥ 3 Radiotherapy-Related Adverse Events (CTCAE v5.0)
Number of Participants With Grade ≥ 3 Systemic Therapy-Related Adverse Events (CTCAE v5.0)
Number of Serious Adverse Reactions (SARs)
Quality-Adjusted Life Years (QALYs)
Healthcare Utilization
Condition-Specific Healthcare Costs
Incremental Cost-Effectiveness Ratio (ICER) of the LAT Strategy
Overall Survival (OS)
Objective Response Rate of the Primary Tumor
Objective Response Rate of Metastases

Arms and interventions

Interventional Arm: Local ablative therapy (LAT) plus systemic therapyExperimental

All patients receive standard first-line systemic therapy according to the molecular analysis of the diagnostic biopsy, per the standard of the treating center. After randomization, patients additionally undergo LAT of the primary tumor and all measurable residual metastases (except PET-negative bone metastases): complete surgical resection of the primary tumor with mediastinal lymph node sampling and/or radical radiotherapy (preferably stereotactic body radiotherapy, SBRT), and surgery and/or SBRT of the metastases. The first LAT is performed within 1 to 35 days after randomization. Choice and sequence of LAT (primary tumor versus metastases) are decided by the local multidisciplinary tumor board (MDT) after interdisciplinary counseling of the patient. Systemic anticancer therapy then continues as standard of care: chemotherapy, chemo-immunotherapy or immunotherapy restarts at the earliest 14 days after LAT; targeted therapy continues throughout.

Control Arm: Systemic therapy aloneActive comparator

Patients receive systemic anticancer therapy alone (chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted therapy), per the standard of the treating center. Local ablative treatment is not allowed. Assigned interventions: Other: Systemic anticancer therapy

Other: Systemic anticancer therapy, Surgery

Radiation: Radiotherapy

Sites

7 sites in 1 country